CAMBRIDGE, Mass. / Oct 16, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2025 results as well as expectations for the... Read More

Global Cardiovascular Outcomes Trial will Enroll ~11,000 Patients Across 35 Countries to Evaluate Zilebesiran as a Novel Biannual Treatment Trial to Assess Zilebesiran in Patients with Uncontrolled Hypertension with Either Established or at High Risk of Cardiovascular Disease Milestone Payment of $300 Million Triggered Under Global Collaboration and License Agreement with Partner Roche CAMBRIDGE, Mass. / Oct 01, 2025 /... Read More

Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo Additional Analyses Reinforce Vutrisiran’s Safety and Efficacy Profile as a Monotherapy and Illustrate Consistent Benefit from Treatment with Vutrisiran Across a Range of Patients’ Baseline Health Status and Quality of Life Findings Presented at the... Read More

CAMBRIDGE, Mass. / Sep 09, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the... Read More

CAMBRIDGE, Mass. / Sep 08, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as... Read More

Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall... Read More

Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 Zilebesiran Displayed Encouraging Safety When... Read More

CAMBRIDGE, Mass. / Aug 27, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025 at 1:45 pm ET in Boston Morgan Stanley 23 rd Annual Global Healthcare Conference on Monday, September... Read More

Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST) CAMBRIDGE, Mass. / Aug 11, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in... Read More

CAMBRIDGE, Mass. / Aug 05, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45 th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s website,... Read More

Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA ® (vutrisiran) as of June 30, 2025 Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan Initiated TRITON-CM Phase 3... Read More

CAMBRIDGE, Mass. / Jul 17, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future... Read More

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease 1 MISSISSAUGA, ON , July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO ® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria... Read More

R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics Goal of Delivering RNAi Therapeutics to All Major Tissues by 2030 CAMBRIDGE, Mass. / Jun 18, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development... Read More

First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy Novel RNAi Mechanism Delivers Rapid Knockdown of Transthyretin (TTR), Addressing the Disease at its Source Approval Based on HELIOS-B Phase 3 Study, Which Showed Up to 36% Reduction in All-Cause Mortality, With Preservation of Functional Capacity and Quality of Life, with Four... Read More

CAMBRIDGE, Mass. / May 28, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46 th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s website,... Read More

– Contains New Disclosures of Company’s Impact on the Environment – Including Independently Verified Scope 1, 2, and 3 Multiyear Data on Greenhouse Gas (GHG) Emissions – – Highlights Progress of Alnylam Challengers Global Health Equity Initiative – CAMBRIDGE, Mass. / May 20, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024... Read More

Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin Additional 42-Month Data Reinforce Vutrisiran’s Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular Events, Notably Reducing Urgent Heart... Read More

CAMBRIDGE, Mass. / May 12, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses... Read More

CAMBRIDGE, Mass. / May 05, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company’s website,... Read More

Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA ® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with... Read More

Recommended Approval Based on the Pivotal HELIOS-B Phase 3 Study in which Vutrisiran Demonstrated Significant Reductions in Mortality and Cardiovascular Events, While Preserving Functional Status and Quality of Life Offers a Clinically Differentiated Approach with Rapid and Sustained Transthyretin (TTR) Knockdown and Quarterly Subcutaneous Dosing Follows Recent Approvals in the U.S. and Brazil European Commission Decision... Read More

CAMBRIDGE, Mass. / Apr 17, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future... Read More

CAMBRIDGE, Mass. / Apr 01, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24 th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s website,... Read More

New Data Follow Recent U.S. FDA Approval of AMVUTTRA ® (vutrisiran) as First RNAi Therapeutic to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Patients with ATTR-CM Vutrisiran Favorably Impacted Echocardiographic Systolic and Diastolic Function Vutrisiran Treatment Led to Maintenance or Improvement in Functional Capacity, Health Status, and Quality of Life, Compared to... Read More

Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors CAMBRIDGE, Mass. / Mar 28, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Qfitlia™ (fitusiran), the sixth... Read More

Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today’s Patients Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis Alnylam Offers Multiple Programs to Support Broad and... Read More

CAMBRIDGE, Mass. / Mar 11, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events . A replay will... Read More

CAMBRIDGE, Mass. / Mar 05, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company’s Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board.... Read More

Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, Cardiovascular Disease, and Neuroscience, each representing a blockbuster opportunity Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the... Read More

Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Representing 30% and 33% Growth Compared to Same Periods in 2023 Supplemental NDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Accepted by FDA, with March 23, 2025 PDUFA Date Reiterates Product Sales and Profitability Guidance and Provides Additional 2025 Financial Guidance... Read More

CAMBRIDGE, Mass. / Jan 30, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well... Read More

Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO ® , AMVUTTRA ® , GIVLAARI ® , and OXLUMO ® , Representing 33% Annual Growth 2025 Combined Net Product Revenue Guidance** of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P 5 x25 Goal of Non-GAAP Profitability Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth CAMBRIDGE, Mass. / Jan 12,... Read More

CAMBRIDGE, Mass. / Nov 27, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36 th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors... Read More

Prescription Drug User Fee Act (PDUFA) Date Set for March 23, 2025 CAMBRIDGE, Mass. / Nov 25, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the... Read More

Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis Encouraging Safety and Tolerability Observed Alnylam... Read More

CAMBRIDGE, Mass. / Nov 04, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT (11:45 ET) at the Terranea Resort in Ranchos Palos Verdes, CA Jefferies London Healthcare Conference on Wednesday, November... Read More

Achieved Third Quarter 2024 Global Net Product Revenues of $420 Million, Representing 34% Year-Over-Year Growth Compared to Q3 2023, Driven by Continued Momentum from TTR Business Submitted Regulatory Applications in U.S. and EU for AMVUTTRA ® (vutrisiran) for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues of $1,575 Million to $1,650... Read More

CAMBRIDGE, Mass. / Oct 30, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA) Scientific Sessions 2024, November 16–18, 2024. Data presentations for the Company’s flagship TTR franchise include new... Read More

CAMBRIDGE, Mass. / Oct 17, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2024 on Thursday, October 31, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2024 results as well as expectations for the... Read More

Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo CAMBRIDGE, Mass. / Oct 16, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA)... Read More

sNDA is Based on Full Findings from the Positive HELIOS-B Phase 3 Study Priority Review Voucher Utilized to Accelerate Review Period Alnylam to Host and Webcast TTR Investor Day Event Today in New York City CAMBRIDGE, Mass. / Oct 09, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the... Read More

Echocardiographic and Cardiac Biomarker Data From the HELIOS-B Study Presented Today Support the Potential of Vutrisiran in ATTR-CM Vutrisiran Significantly Improved Echocardiographic Assessments of Cardiac Structure, Systolic Function and Diastolic Function Relative to Placebo Over 30 Months Vutrisiran Demonstrated Relative Stability of Cardiac Biomarkers NT-proBNP and Troponin-I Relative to Placebo Over 30 Months... Read More

CAMBRIDGE, Mass. / Sep 26, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the Investors section of the Company’s website, www.alnylam.com , on Wednesday, October 9, 2024 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Day... Read More

In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period and up to Month 42, Respectively In the Monotherapy Population, Reduced Composite Primary Endpoint by 33% and All-Cause Mortality up to Month 42 by 35% Strong Trends of Additive Efficacy on Top of... Read More

CAMBRIDGE, Mass. / Aug 28, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 9:30 am ET in Boston Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 1:05 pm ET in... Read More

Company to Host Conference Call on August 30, 2024, at 1:00 p.m. (BST), 8:00 a.m. (ET) to Discuss Results CAMBRIDGE, Mass. / Aug 07, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present results from the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy at the European Society of... Read More

Achieved Second Quarter 2024 Global Net Product Revenues of $410 Million, Representing 34% Year-Over-Year Growth Compared to Q2 2023, Driven by Continued Momentum from TTR Business, Which Delivered 37% Year-Over-Year Growth – Reported Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations –... Read More

CAMBRIDGE, Mass. / Jul 18, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2024 results as well as expectations for the... Read More

Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy Populations, Respectively Reduced All-Cause Mortality by 36% and 35% in the Overall and Monotherapy Populations, Respectively, in a Pre-Specified Secondary Endpoint Demonstrated Clinically Significant Benefits on 6-Minute Walk Test, Kansas City Cardiomyopathy Questionnaire and NYHA Class – Key... Read More

Highlighted New Disclosures of Company’s Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy, Water, and Waste Management Footprint Expanded Alnylam Challengers Global Health Equity Initiative CAMBRIDGE, Mass. / May 07, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate... Read More

Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year-Over-Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year-Over-Year Growth Demonstrated Strong Progress with Zilebesiran Hypertension Program with Positive Results from KARDIA-2 Phase 2 Study and Initiation of KARDIA-3 Phase 2 Study Remain on Track to Report Topline Results from HELIOS-B... Read More

The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam's innovative RNAi technologies ZUG, Switzerland , April 30, 2024 /CNW/ -- Medison Pharma ("Medison"), a global pharma... Read More

CAMBRIDGE, Mass. / Apr 18, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future... Read More

Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 A Single Dose of Zilebesiran Resulted in Clinically Significant Additive Reductions in Office Systolic Blood Pressure at Month 3 and in Time-Adjusted Office Systolic Blood Pressure at Month 6 Across Three Independent Study Cohorts... Read More

CAMBRIDGE, Mass. / Mar 20, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology... Read More

Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health Genealogist and Health Educator Bernice Bennett Travels Cross-Country to Visit Members of hATTR Amyloidosis Community and Highlight How Discussing Family Health History Can Drive... Read More

Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added to a Diuretic, Calcium-Channel Blocker or Angiotensin Receptor Blocker Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile When Added to Standard of Care Antihypertensives Study Results Support Potential for Biannual Dosing of Zilebesiran Full Study Results to Be... Read More

CAMBRIDGE, Mass. / Feb 27, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: TD Cowen 44 th Annual Health Care Conference on Tuesday, March 5, 2024 at 9:10 am ET in Boston Barclays 26 th Annual Global Healthcare Conference on Tuesday, March 12, 2024 at 10:15 am ET in Miami... Read More

Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 Company Announces Updated Statistical Analysis Plan and Timing for HELIOS-B Phase 3 Study of Vutrisiran Announces U.S. FDA Clearance to Initiate Multiple-Dosing in ALN-APP Phase 1 Study Provides 2024 Combined Net Product Revenue Guidance of $1,400 Million to... Read More

CAMBRIDGE, Mass. / Jan 29, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2023 on Thursday, February 15, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2023 results as well... Read More

CAMBRIDGE, Mass. / Jan 09, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA). The announcement was made last evening at the J.P. Morgan Healthcare Conference in San Francisco. Yvonne will be recognized at HBA’s... Read More

Achieved Full Year 2023 Preliminary Global Net Product Revenues of $1,241 Million for ONPATTRO ® , AMVUTTRA ® , GIVLAARI ® , and OXLUMO ® , Representing 39% Annual Growth (39% Using Constant Exchange Rate**) Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.4 Billion CAMBRIDGE, Mass. / Jan 07, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi... Read More

CAMBRIDGE, Mass. / Jan 02, 2024 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on... Read More

Company Anticipates Investigational New Drug (IND) Applications for Nine or More Programs with Targets Expressed in the Liver, Central Nervous System, Adipose Tissue, and Muscle by End of 2025 Positive Initial Phase 1 Results with ALN-TTRsc04 Demonstrate Rapid Knockdown with Mean Serum TTR Reduction up to 97% with Durability Supporting Potential for Annual Dosing and an Encouraging Safety Profile Positive Initial Phase 1... Read More

CAMBRIDGE, Mass. / Dec 06, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com , on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam... Read More

Recognition Marks Alnylam’s Ninth Year in a Row on this Prestigious List, and the Third Consecutive Year Ranking #1 CAMBRIDGE, Mass. / Nov 30, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the “Largest Employer” category. This marks the third year in a row that Alnylam has taken the top... Read More

Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean Systolic Blood Pressure at Three Months of Treatment Study Met Key Secondary Endpoints Showing Consistent and Sustained Reductions of Systolic Blood Pressure and Durable Tonic Blood Pressure Control Through Month 6 Data Support Quarterly or Biannual Dosing Zilebesiran Demonstrated an Encouraging Safety and Tolerability... Read More

CAMBRIDGE, Mass. / Nov 07, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc . (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 10:00 am GMT (5:00 am ET) in London Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 9:45 am ET at the Lotte... Read More

Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 Received Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Company Remains On Track to Report Topline Results from HELIOS-B Phase 3 Study in Early 2024 Reported Positive Topline Results from... Read More

Annual Survey has Ranked Alnylam within the Top Three on the Best Employers List Since 2019 CAMBRIDGE, Mass. / Oct 26, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its third place ranking in Science magazine’s Top Employer Survey for 2023. This marks the fifth year that Alnylam was featured as one of the top three companies in the annual survey of more... Read More

Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosis CAMBRIDGE, Mass. / Oct 25, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results... Read More

Single Doses of ALN-APP Achieve Sustained Pharmacodynamic Activity up to 10 Months After Administration Observed Marked Reductions in Aβ 42 and Aβ 40 , Amyloid Fragments Implicated in Alzheimer’s Disease and Cerebral Amyloid Angiopathy First Patient Dosed in Multiple-dose Part B Portion of Study, with the Study Proceeding in Canada, UK, and the Netherlands CAMBRIDGE, Mass. / Oct 25, 2023 / Business Wire / Alnylam... Read More

CAMBRIDGE, Mass. / Oct 19, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2023 results as well as expectations for the... Read More

FDA Cites Insufficient Evidence of Clinical Meaningfulness No Clinical Safety, Study Conduct, Drug Quality or Manufacturing Issues Identified CRL Does Not Pertain to, nor Impact Commercial Availability of, ONPATTRO ® (patisiran) for Existing Indication for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis in Adults Alnylam to Host Investor Conference Call Today, Monday, October 9, 2023 at 8:30 a.m. ET... Read More

CAMBRIDGE, Mass. / Oct 06, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new results for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM)... Read More

Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Prescription Drug User Fee Act Target Action Date is October 8, 2023 CAMBRIDGE, Mass. / Sep 13, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the positive outcome of the U.S. Food... Read More

CAMBRIDGE, Mass. / Sep 13, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee is meeting today to review the supplemental New Drug Application for patisiran, an investigational RNAi therapeutic in... Read More

Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated Study Met Key Secondary Endpoints Showing Consistent and Sustained Reductions of Systolic Blood Pressure at Six Months, Supporting Quarterly or Biannual Dosing Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile in... Read More

CAMBRIDGE, Mass. / Aug 25, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation. On March 17, 2022, Alnylam initiated litigation in the United States District Court for the District of Delaware against Moderna for patent infringement. To date, in two separate actions against Moderna, Alnylam has... Read More

Achieved Second Quarter 2023 Global Net Product Revenues of $306 Million, Representing 43% Year-Over-Year Growth Compared to Q2 2022 Submitted 18-Month APOLLO-B Data to the U.S. Food and Drug Administration as Amendment to Supplemental New Drug Application for Patisiran Presented Updated Positive Interim Results from Phase 1 Study of ALN-APP in Patients with Early-Onset Alzheimer’s Disease Entered into Global Strategic... Read More

CAMBRIDGE, Mass. / Aug 02, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43 rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston. A live audio webcast of the presentation will be available on the Investors section of... Read More

Partnership Combines Alnylam’s Leadership in RNAi Therapeutics with Roche’s Proven Track Record of Successfully Developing and Launching Innovative Medicines Worldwide Zilebesiran Represents a Potentially Transformative Approach to Reducing CV Morbidity and Mortality in Hypertension Patients at High CV Risk by Robustly and Durably Lowering Blood Pressure Alnylam will Receive an Upfront Cash Payment of $310 Million and is... Read More

CAMBRIDGE, Mass. / Jul 20, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2023 on Thursday, August 3, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2023 results as well as expectations for the... Read More

Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran Acceptable Safety Profile Supporting Further Development CAMBRIDGE, Mass. / Jul 19, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from its Phase 1 study of zilebesiran, an... Read More

First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profile Multiple-dose Portion of Study, Part B, Being Initiated in Approved Regions CAMBRIDGE, Mass. / Jul 17, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc.... Read More

CAMBRIDGE, Mass. / Jun 30, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an investigational treatment for the cardiomyopathy of... Read More

CAMBRIDGE, Mass. / Jun 05, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT (11:00 am ET) at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. A live audio webcast of the presentation... Read More

Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months Safety Profile Consistent with that Observed in 12-Month Double-Blind Period, with No New Safety Findings CAMBRIDGE, Mass. / May 20, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc.... Read More

Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 Reported Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy, Establishing First-Ever Human Translation of RNAi Therapeutics in CNS Reiterated 2023 Financial Guidance, Including Combined Net Product... Read More

CAMBRIDGE, Mass. / May 03, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas. A live audio webcast of the presentation will be available on the Investors section of the... Read More

Successfully Met Goals Outlined in MassBio’s Diversity, Equity, and Inclusion (DE&I) Industry Pledge New Disclosures of Company’s Impact on Planet—Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions CAMBRIDGE, Mass. / May 03, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility... Read More

Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform Alnylam to Host Conference Call Today... Read More

CAMBRIDGE, Mass. / Apr 20, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2023 results as well as expectations for the future... Read More

ZUG, Switzerland , March 9, 2023 /CNW/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary , Slovakia ,... Read More

CAMBRIDGE, Mass. / Mar 08, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. “Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to... Read More

CAMBRIDGE, Mass. / Feb 23, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights. “2022 was another year of strong progress at Alnylam, including our continued commercial execution which delivered 35% full-year product... Read More

CAMBRIDGE, Mass. / Feb 21, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR)... Read More

CAMBRIDGE, Mass. / Feb 02, 2023 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2022 results as well... Read More

Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO ® , AMVUTTRA ® , GIVLAARI ® , and OXLUMO ® , Representing 35% Annual Growth (43% Using Constant Exchange Rate**) Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth – Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.2 Billion Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),... Read More

Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies Michael W. Bonney Steps Down as Executive Chair and Continues on Board as Non-Independent Director Amy W. Schulman will Assume Role of Chair of the Board Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, today announces appointment of Carolyn Bertozzi,... Read More

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2022... Read More

Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting... Read More

sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi... Read More